Opin vísindi

Circulating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

Show simple item record

dc.contributor.author Scheffler, Julia M.
dc.contributor.author Drevinge, Christina
dc.contributor.author Lindholm, Catharina
dc.contributor.author Gjertsson, Inger
dc.contributor.author Lend, Kristina
dc.contributor.author Lund Hetland, Merete
dc.contributor.author Østergaard, Mikkel
dc.contributor.author Uhlig, Till
dc.contributor.author Schrumpf Heiberg, Marte
dc.contributor.author Haavardsholm, Espen A.
dc.contributor.author Nurmohamed, Michael T.
dc.contributor.author Lampa, Jon
dc.contributor.author Sokka-Isler, Tuulikki
dc.contributor.author Nordström, Dan
dc.contributor.author Hørslev-Petersen, Kim
dc.contributor.author Guðbjörnsson, Björn
dc.contributor.author Gröndal, Gerður María
dc.contributor.author van Vollenhoven, Ronald
dc.contributor.author Carlsten, Hans
dc.contributor.author Lorentzon, Mattias
dc.contributor.author Hultgård Ekwall, Anna Karin
dc.contributor.author Rudin, Anna
dc.contributor.author Islander, Ulrika
dc.date.accessioned 2024-12-07T01:03:53Z
dc.date.available 2024-12-07T01:03:53Z
dc.date.issued 2025-01
dc.identifier.citation Scheffler , J M , Drevinge , C , Lindholm , C , Gjertsson , I , Lend , K , Lund Hetland , M , Østergaard , M , Uhlig , T , Schrumpf Heiberg , M , Haavardsholm , E A , Nurmohamed , M T , Lampa , J , Sokka-Isler , T , Nordström , D , Hørslev-Petersen , K , Guðbjörnsson , B , Gröndal , G M , van Vollenhoven , R , Carlsten , H , Lorentzon , M , Hultgård Ekwall , A K , Rudin , A & Islander , U 2025 , ' Circulating Baseline CXCR3 + Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis ' , ACR Open Rheumatology , vol. 7 , no. 1 , e11742 . https://doi.org/10.1002/acr2.11742
dc.identifier.issn 2578-5745
dc.identifier.other 230980839
dc.identifier.other 6a51c2c6-9e5b-4c3c-9f5a-6cd372c7e7a9
dc.identifier.other 85206689823
dc.identifier.other 39411912
dc.identifier.uri https://hdl.handle.net/20.500.11815/5161
dc.description Publisher Copyright: © 2024 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
dc.description.abstract Objective: The high prevalence of osteoporosis in rheumatoid arthritis (RA) is due to inflammation that stimulates differentiation of osteoclasts, a process involving circulating monocytes and T cell–derived factors. The aim of this study was to evaluate relations between circulating monocytes, T cell subsets, and changes in bone characteristics before and after treatment with biological disease-modifying antirheumatic drugs (bDMARDs) in RA. Methods: Thirty patients with untreated early RA who met the American College of Rheumatology/EULAR 2010 criteria were included. Data were collected before and 48 weeks after treatment with methotrexate (MTX) together with one of three bDMARDs (abatacept, tocilizumab, or certolizumab pegol). Disease activity was measured using the Clinical Disease Activity Index, swollen or tender joint counts, C-reactive protein levels, and erythrocyte sedimentation rates. Proportions of monocyte and CD4+ T cell subsets in blood samples were analyzed by flow cytometry. Bone densitometry was performed using high-resolution peripheral quantitative computed tomography (HR-pQCT). Results: HR-pQCT revealed an overall decrease in cortical (P = 0.009) and trabecular (P = 0.034) bone mineral density, although a subset of patients showed no bone loss after 48 weeks of treatment. The overall bone loss was not associated with age, body mass index, sex, intraarticular glucocorticoid injections, or baseline disease activity. Loss of trabecular bone volume fraction correlated with high proportions of circulating CXCR3+Th2 cells (r = −0.38, P = 0.04) and CXCR3+Th17 cells (r = −0.36, P = 0.05) at baseline. Similarly, no loss of trabecular bone volume fraction correlated with high proportions of regulatory T cells (r = 0.4, P = 0.03) at baseline. However, the associations were not significant when corrected for confounders and multiple testing. Conclusion: MTX together with bDMARDs efficiently reduce disease activity but only prevent bone loss in a subset of patients with RA after 48 weeks of treatment. The correlations of circulating baseline T helper cell and regulatory T cell populations with trabecular bone changes suggest a potential novel role for these cells in systemic bone homeostasis during early RA.
dc.format.extent 1637925
dc.format.extent
dc.language.iso en
dc.relation.ispartofseries ACR Open Rheumatology; 7(1)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Gigtarlæknisfræði
dc.subject Rheumatology
dc.title Circulating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1002/acr2.11742
dc.relation.url http://www.scopus.com/inward/record.url?scp=85206689823&partnerID=8YFLogxK
dc.contributor.department Other departments
dc.contributor.department Faculty of Medicine


Files in this item

This item appears in the following Collection(s)

Show simple item record